Sofinnova Venture Partners — Full Portfolio
5 tracked investments · listed companies and verified rows first
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)
Board seatAnand Mehra· per SEC Form D · $11.4M raise · filed Apr 2020
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalRA CapitalSofinnova Ventures+1 more
Developing broad-spectrum antifungal agents for invasive fungal infections.
BiotechSan Diego, US
Mitchell Mutz(Executive Officer, Director)
BoardChrysa Mineo(Director)Jack Florio(Director)Elaine Heron(Director)Santosh Vetticaden(Director)Karen Talmadge(Director)
Board seatAnand Mehra· per SEC Form D · $102.7M raise · filed Jan 2020
Co-investorsNew Enterprise Associates (NEA)Pappas CapitalRiverVest Venture PartnersSofinnova Ventures
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)Corey N. Fishman(Executive Officer, Director, Promoter)Judith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Board seatJames I. Healy· per SEC Form D · $47.6M raise · filed Dec 2016
Co-investorsBay City CapitalCanaan PartnersSofinnova VenturesFrazier Life Sciences
BiotechHamilton
Brenton K. Ahrens(Director)James I. Healy(Director)Mark Chin(Director)Patrick J. Heron(Director)inRonald M. Hunt(Director)Shahzad Malik(Director)
Board seatJames I. Healy· per SEC Form D · $51.6M raise · filed Jan 2020
Co-investorsFrazier Life Sciences
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)Leon Chen, Ph.D.(Director)Carol Gallagher(Director)Joshua Resnick, M.D.(Director)
Board seatMichael Powell· per SEC Form D · $62M raise · filed Dec 2017
Co-investorsMission Bay CapitalMission BiocapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.